Albert Einstein College of Medicine

Vial Announces the Addition of Dr. Adam Friedman of the George Washington University School of Medicine and Health Sciences to their Dermatology CRO Scientific Advisory Board

Retrieved on: 
Wednesday, November 30, 2022
Translational research, SAN, Cardiology, George Washington University School of Medicine & Health Sciences, SAB, Hospital, United States Air Force Scientific Advisory Board, Multimedia, Cannabinoid, Education, Faculty, Nanotechnology, Ophthalmology, Outline of health sciences, Research, Gastroenterology, Albert Einstein College of Medicine, Cras, Neurology, Entrepreneurship, Fine chemical, Medical device, Vial, MD, Dermatology

SAN FRANCISCO, Nov. 29, 2022 /PRNewswire/ -- Vial , a tech-enabled CRO providing next-generation clinical trial management services, announced the addition of Adam Friedman, MD, to their Scientific Advisory Board.

Key Points: 
  • SAN FRANCISCO, Nov. 29, 2022 /PRNewswire/ -- Vial , a tech-enabled CRO providing next-generation clinical trial management services, announced the addition of Adam Friedman, MD, to their Scientific Advisory Board.
  • Dr. Friedman will advise Vial on enhancing its Dermatology CRO product and services.
  • Dr. Friedman holds multiple titles at the George Washington University School of Medicine and Health Sciences.
  • Vial operates across multiple Therapeutic Areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , and Cardiology CRO ).

Ayal Willner, MD is recognized by Continental Who's Who

Retrieved on: 
Monday, November 28, 2022
American Academy of Otolaryngology–Head and Neck Surgery, Tonsillectomy, Head, Otorhinolaryngology, Hospital, American College, ENT, Sleep apnea, Multimedia, Le Bonheur Children's Hospital, Long Beach Memorial Medical Center, George Washington University, Education, Society, Miller Children's Hospital, MD, Cornell University, American Board of Commissioners for Foreign Missions, Fellowship of the Royal Colleges of Surgeons, Assistant, Private practice, Mending Kids International, Albert Einstein College of Medicine, American Academy, National Institute of Ear, Nose and Throat (ENT), Bangladesh, Interventional cardiology, Continental, Pediatrics (journal), Medicine, Dentistry, Pediatrics, Child, Biology

LONG BEACH, Calif., Nov. 28, 2022 /PRNewswire/ -- Ayal Willner, MD, is being recognized by Continental Who's Who as a Distinguished Otolaryngologist, Partner, and Owner in the medical field and in acknowledgment of his professional excellence at Southern California Ear Nose and Throat (SCENT).

Key Points: 
  • LONG BEACH, Calif., Nov. 28, 2022 /PRNewswire/ -- Ayal Willner, MD, is being recognized by Continental Who's Who as a Distinguished Otolaryngologist, Partner, and Owner in the medical field and in acknowledgment of his professional excellence at Southern California Ear Nose and Throat (SCENT).
  • Dr. Willner is a Pediatric Otolaryngologist specialist with his own private practice called Southern California Ear Nose and Throat (SCENT).
  • Dr. Ayal Willner began his college education at Cornell University, graduating with a Bachelor of Science degree in Biology.
  • He later received his medical degree and completed an Otolaryngology residency at the Albert Einstein College of Medicine.

Viz.ai Launches AI-powered Viz™ Radiology Suite

Retrieved on: 
Monday, November 28, 2022
Medical Devices, Health, Oil, Gas, Health Technology, Energy, Radiology, Doctor of Philosophy, Interventional Neuroradiology, Diagnosis, Neurosurgery, Albert Einstein College of Medicine, AI, Multimedia, Machine learning, Hospital, Health, Patient, Montefiore Medical Center, Radiology, Workflow, Disease, PACS, FDA, Algorithm, Medical imaging

The Viz Radiology Suite integrates into the picture archiving and communication systems (PACS) of healthcare organizations to securely facilitate access to imaging data across departments and streamline patient diagnosis.

Key Points: 
  • The Viz Radiology Suite integrates into the picture archiving and communication systems (PACS) of healthcare organizations to securely facilitate access to imaging data across departments and streamline patient diagnosis.
  • The Viz Radiology Suite offers radiologists important capabilities for optimizing imaging data and accelerating patient assessments with robust AI-powered features, such as real-time notifications, easy-to-use communication tools, and prioritized worklists.
  • The Viz Radiology Suite provides a mobile and web image viewer with AI-powered notifications directly to the worklist, and integration with PACS, enabling efficient care coordination.
  • As a result, we are excited to offer the Viz Radiology Suite, an AI-powered set of capabilities specifically designed for radiologists to advance patient care.

Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, FDA, Medication, Clinical trial, Summit Medical Group, Brain, Epilepsy, Ganaxolone, J. P. Morgan, CDKL5, Prescription, Albert Einstein College of Medicine, Annual report, Prodrug, Rachel Haurwitz, Security (finance), Marinus, Form 10-K, FTSE Global Equity Index Series, IV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Columbia University Irving Medical Center, Therapy, Trevena Inc, Growth, COVID-19, CV, Seizure, GABAA, Risk, EMA, Food, Patient, Management, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Chairman of the Board.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Chairman of the Board.
  • Newly appointed Lead Independent Board Director for Marinus, Tim M. Mayleben, said, "We are thrilled with the Companys transformation over the last few years under Scotts management.
  • We look forward to complementing the skills and expertise of the Board with new members to support efforts to scale Marinus.
  • I look forward to working with Tim as we evolve and enhance the Marinus Board with additional capabilities, said Chairman and CEO, Scott Braunstein.

BAKX Welcomes Dr. Marina Konopleva to Its Scientific Advisory Board

Retrieved on: 
Wednesday, November 16, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, College of Medicine, Leukemia, Lymphoma, Acute myeloid leukemia, Therapy, AML, Multimedia, Albert Einstein College of Medicine, Cancer, Degenerative disease, Neoplasm, Research, Apoptosis, Metabolism, Faculty, Drug discovery, BAX, Knowledge, Pharmaceutical industry, Venetoclax

BAKX Therapeutics, a company developing safer, more effective therapeutics that fully realize the potential of the mitochondrial apoptosis pathway, announced Marina Konopleva, M.D., Ph.D., Albert Einstein College of Medicine joined the companys Scientific Advisory Board.

Key Points: 
  • BAKX Therapeutics, a company developing safer, more effective therapeutics that fully realize the potential of the mitochondrial apoptosis pathway, announced Marina Konopleva, M.D., Ph.D., Albert Einstein College of Medicine joined the companys Scientific Advisory Board.
  • Were excited by her enthusiasm for our platform and discovery programs, and we are honored to welcome her to BAKXs Scientific Advisory Board.
  • Evripidis Gavathiotis, Ph.D., BAKX scientific co-founder and chief science advisor, said, I am very pleased to welcome Dr. Konopleva to the BAKX Scientific Advisory Board, just months after welcoming her as a colleague to the faculty of Albert Einstein College of Medicine and Montefiore Einstein Cancer Center.
  • BAKX was co-founded by world leading researchers in the field of apoptosis and computational drug discovery.

Albert Einstein College of Medicine Researchers Develop Promising New Cancer Therapy

Retrieved on: 
Tuesday, November 15, 2022
Albert Einstein College of Medicine, Technology, NK, Immunotherapy, Immunity, Student, YouTube, Microbiology, College, Melanoma, Ageing, Squamous cell carcinoma, University Hospital (Newark, New Jersey), AIDS, Diabetes, National, Lung, Attention, Lymphoma, PVR, Stomach, Partnership, Myeloid leukemia, Liver disease, Patient, Degenerative disease, Protein, Pembrolizumab, Paper, Pancreatic cancer, College of Medicine, Doctor of Philosophy, Montefiore, Microdeletion syndrome, Journal, Urology, Teaching hospital, Journal of Clinical Investigation, Multimedia, College of Medicine (UK), Head, Neuroscience, Neoplasm, JCI, Neck, TIGIT, Acute myeloid leukemia, Research, Patent, Albert Einstein, Large-cell lung carcinoma, Cancer research, Pharmaceutical industry, Vaccine, Cancer, Medicine, Facebook

Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement.

Key Points: 
  • Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement.
  • In a paper published online today in The Journal of Clinical Investigation (JCI), scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy.
  • Rather than rally T cells against cancer, the Einstein research team used different human immune cells known as natural killer (NK) cellswith dramatic results.
  • About Albert Einstein College of Medicine Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation.

Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022

Retrieved on: 
Tuesday, November 1, 2022
Population, Liver disease, GLOBE, EC, Department, Health care, Alagille syndrome, Food, Safety, Albert Einstein College of Medicine, Ageing, BSEP, Institute of Liver and Biliary Sciences, Liver, MHRA, Adult, Primary biliary cholangitis, Abdominal pain, Nasdaq, American Association for the Study of Liver Diseases, Incidence, Diarrhea, Digital, University Medical Center Groningen, PFIC, Vomiting, FSV, Biliary atresia, Abstract, BOLD, AASLD, Pediatrics, Public, Diagnosis, Vitamin, Data analysis, Augmented fifth, European Commission, Dehydration, Medicine, ABCB11, 2021 Essex County Council election, Itch, Association, American Association, Pharmaceutical industry, Dietary supplement, Medical imaging, Patient, Montefiore

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the acceptance of two late breakers, including one late breaker with new data from the Phase 3 ASSERT study, to be presented as an oral presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2022, November 4 – 8, 2022. Positive topline results from ASSERT, a global, double-blind, randomized, placebo-controlled trial which evaluated the safety and efficacy of Bylvay in ALGS patients from birth to early adulthood, were announced in October. A second late breaker was also accepted as an oral presentation with data showing Bylvay restored biliary bile acid secretion in treatment-responsive progressive familial intrahepatic cholestasis (PFIC) patients with bile salt export pump (BSEP) deficiency in the PEDFIC 1 trial. A third oral presentation was previously announced, with a pooled data analysis of the PEDFIC trials showing that a decrease in serum bile acids was strongly associated with native liver survival in PFIC patients treated with Bylvay.

Key Points: 
  • A full list of presentations can be found on The Liver Meeting Digital Experience 2022 website .
  • A potent, once-daily, non-systemic ileal bile acid transport inhibitor, Bylvay has minimal systemic exposure and acts locally in the small intestine.
  • The most common adverse reactions for Bylvay are diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency.
  • Bylvay was well tolerated, with an overall adverse event incidence similar to placebo and a low incidence of drug-related diarrhea (11.4% vs. 5.9% placebo).

Compassionate Oncology Medical Group Joins Los Angeles Cancer Network

Retrieved on: 
Tuesday, November 1, 2022
MD, CEO, Ronald Reagan UCLA Medical Center, Multiple myeloma, Cancer, Physician, Institute, Hematology, University of California, Research, View, Suite, Cedars-Sinai Medical Center, University, Degenerative disease, Association of College Honor Societies, Patient, Multimedia, Albert Einstein College of Medicine, Ronald Reagan, Medical device, Medicine

LOS ANGELES, Nov. 1, 2022 /PRNewswire/ -- Los Angeles Cancer Network (LACN), one of the leading cancer treatment centers in Los Angeles, is proud to announce that Compassionate Oncology Medical Group and board-certified medical oncologist & hematologist Shahrooz Eshaghian, MD FACP, have officially joined it's growing network.

Key Points: 
  • LOS ANGELES, Nov. 1, 2022 /PRNewswire/ -- Los Angeles Cancer Network (LACN), one of the leading cancer treatment centers in Los Angeles, is proud to announce that Compassionate Oncology Medical Group and board-certified medical oncologist & hematologist Shahrooz Eshaghian, MD FACP, have officially joined it's growing network.
  • This new addition to LACN is locatedat 2080 Century Park E, Suite 1005, Los Angeles, CA 90067.
  • Los Angeles Cancer Network Welcomes Dr. Shahrooz Eshaghian
    "We are extremely proud to have Dr. Eshaghian and his dedicated team at Compassionate Oncology Medical Group join our network," said Troy Simon, LACN's CEO.
  • Dr. Eshaghian graduated summa cum laude from University of California, Los Angeles with College Honors and Phi Beta Kappa.

Skin Expert Dr. Cameron Rokhsar Joins Exclusive Haute Beauty Network

Retrieved on: 
Thursday, October 20, 2022
Physician, Chin, Medicine, Self-signed certificate, U.S. News & World Report, Lenox Hill Hospital, ABC News, Mohs surgery, CBS News, Research, Nose, Private practice, Albert Einstein College of Medicine, Haute Living, Today, Eyelid, Mount Sinai Hospital, Education, Fox News, Castle, Harvard University, Television, Associate, News, Beauty, New York University School of Law, NBC News, Acne, Skin cancer, Good Morning America, Fashion, Veterinary medicine, Dermatology, New York (magazine), Fraxel

MANHATTAN, N.Y., Oct. 20, 2022 /PRNewswire-PRWeb/ -- Dr. Cameron K. Rokhsar, M.D., F.A.A.D., F.A.A.C.S., an internationally renowned laser surgeon, is a double Board Certified dermatologist, dermatologic mohs surgeon, and fellowship-trained cosmetic and laser surgeon in private practice in Manhattan and Long Island. He practices cosmetic and general dermatology with a particular focus on laser and other nonsurgical treatments, aesthetic enhancements with fillers, skin cancer, and its treatment through Mohs Micrographic Surgery, minimally invasive liposuction, and the treatment of acne and acne scars. Dr. Rokhsar is an Associate Professor of Dermatology at Mount Sinai Hospital, where he teaches the cosmetic dermatology clinic.

Key Points: 
  • Dr. Cameron Rokhsar joins Haute Beauty Network as a skin expert representing the Manhattan, NY market.
  • Dr. Rokhsar is an Associate Professor of Dermatology at Mount Sinai Hospital, where he teaches the cosmetic dermatology clinic.
  • As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.
  • For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/
    Brooke Klaiman, Haute Beauty by Haute Living, 5612122126, [email protected]

CCRM Fertility Grows its Award-Winning Team of Physicians in New York

Retrieved on: 
Tuesday, October 11, 2022
Physician, Reproductive health, Yale University, History of medicine, Medicine, Obstetrics, Health care, Woman, Science, Hope, Joseph, Education, Reproductive biology, NYU, Gynaecology, New York University Grossman School of Medicine, Patient, Emil Steinberger (endocrinologist), Research, Reproductive rights, Multimedia, Albert Einstein College of Medicine, NEW, Columbia University, Reproduction, Young professional, Reproductive technology, CEO, Awareness, Arnold, IVF, Fertility, Genetic testing, Journal, Infertility, Endocrinology, View, Birth control, Pharmaceutical industry, Genetics

NEW YORK, Oct. 11, 2022 /PRNewswire/ -- CCRM Fertility, a global pioneer in fertility treatment, research and science, expands its New York team with the addition of Dr. Arielle Bayer. She is board certified in obstetrics and gynecology, and board-eligible in reproductive endocrinology and infertility. A New York City native, Dr. Bayer is now accepting new patients at CCRM Fertility in New York.

Key Points: 
  • A New York City native, Dr. Bayer is now accepting new patients at CCRM Fertility in New York.
  • "With Dr. Bayer joining our acclaimed group of physicians, we can help even more families in New York achieve their family-building goals," said Jon Pardew, president and CEO of CCRM Fertility.
  • "Her compassion for patients and outstanding clinical acumen will have an immediate impact on patients seeking high quality fertility treatments."
  • CCRM Fertility in New York is located at 810 7th Ave., 21st Floor, New York, NY 10019.